Logo

Medtronic Reports Results of Symplicity Renal Denervation System in Two Studies for Hypertensive Heart Diseases

Share this

Medtronic Reports Results of Symplicity Renal Denervation System in Two Studies for Hypertensive Heart Diseases

Shots:

  • The two studies include investigator-led study & Global SYMPLICITY Registry results involves the assessing of Symplicity renal denervation system vs sham in 80 & 2-600 patients with uncontrolled hypertension
  • Collective results: atrial fibrillation (AF) occurrence (19% vs 47%); reductions in both office and ambulatory blood pressure (16.5 mm Hg OSBP and 8.9 mm Hg 24H systolic ABPM)- sustained reduction in BP in diabetes- ISH- CKD; safe & effective- presented at EuroPCR- 2019
  • Medtronic’s Symplicity is also evaluated 70-patient SYMPLICITY AF study assessing renal denervation system in patients with paroxysmal and persistent atrial fibrillation and is approved in 50+ countries

Ref: Medtronic | Image: Twitter

Click here to­ read the full press release 

Senior Editor

This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com

Share this article on WhatsApp, LinkedIn and Twitter

Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions